New mRNA boosters aim to strengthen COVID-19 protection
NCT ID NCT05960097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested several new mRNA COVID-19 booster vaccines in 692 healthy adults who had already received a primary vaccine series. The goal was to compare the safety and immune response of these experimental boosters against a control vaccine. Participants received a single injection, and researchers measured antibody levels and tracked side effects like pain, fever, and fatigue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA COVID-19 vaccine (CV0701, CV0601, CV0801)
- What this could lead to
- If successful, this could lead to a new, effective COVID-19 booster option that strengthens protection against the virus.
- What could go wrong
- This is an early-phase trial with only 692 participants, so results may not apply to everyone. The vaccines may not provide better protection than existing boosters, and side effects like injection site pain or fatigue are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Sacramento, California, 95864, United States
-
GSK Investigational Site
Hollywood, Florida, 33024, United States
-
GSK Investigational Site
Peoria, Illinois, 61614-4896, United States
-
GSK Investigational Site
Bruce, Australian Capital Territory, 2617, Australia
-
GSK Investigational Site
Blacktown, New South Wales, 2148, Australia
-
GSK Investigational Site
Botany, New South Wales, 2019, Australia
-
GSK Investigational Site
Brookvale, New South Wales, 2100, Australia
-
GSK Investigational Site
Coffs Harbour, New South Wales, 2450, Australia
-
GSK Investigational Site
Darlinghurst, New South Wales, 2010, Australia
-
GSK Investigational Site
Kanwal, New South Wales, 2259, Australia
-
GSK Investigational Site
Maroubra, New South Wales, 2035, Australia
-
GSK Investigational Site
Merewether, New South Wales, 2291, Australia
-
GSK Investigational Site
Blacktown, Queensland, 4006, Australia
-
GSK Investigational Site
Sherwood, Queensland, 4068, Australia
-
GSK Investigational Site
Tarragindi, Queensland, 4075, Australia
-
GSK Investigational Site
Adelaide, South Australia, 5000, Australia
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?